Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2016-03-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（二）
Board/Management Information Classification · 95% confidence The document is a public statement from the board of 华兰生物工程股份有限公司 nominating a candidate for independent director. It contains detailed declarations about the nominee's qualifications, compliance with laws and regulations, and independence criteria. There are no financial statements, earnings data, or report attachments. The content is related to board/management information, specifically about a board nomination. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is about 4995 characters, which is sufficient for a detailed announcement but not a full report.
2016-03-29 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an internal control rules implementation self-inspection form from a company named 华兰生物工程股份有限公司, dated March 28, 2016. It contains detailed internal control checklists related to internal audit operations, information disclosure, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. There are no financial statements, earnings data, or management discussion of financial results. The document is a compliance/internal control report rather than a financial report or announcement. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a regulatory filing or announcement either but a detailed internal control self-assessment report. Given the content, it best fits under Regulatory Filings (RNS) as a general compliance/internal control disclosure that does not fit other specific categories.
2016-03-29 Chinese
第五届监事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 21st meeting of the 5th Supervisory Board of Hualan Biological Engineering Inc. It includes voting results on various reports such as the 2015 Supervisory Board Work Report, 2015 Annual Report and Summary, 2015 Financial Final Accounts Report, and other internal control and investment proposals. It also announces the nomination of candidates for the 6th Supervisory Board. The document is not the actual annual report or financial statements but a meeting resolution announcement related to governance and supervisory board activities. It does not contain detailed financial data or the full annual report itself. Therefore, it fits best under Board/Management Information (MANG) as it relates to supervisory board meeting resolutions and management nominations.
2016-03-29 Chinese
独立董事对公司相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion report on various company matters including related party transactions, external guarantees, internal control evaluation, appointment of auditors, investment and financing, cash dividend proposal, guarantees for affiliated companies, and opinions on board candidates. It references regulatory guidelines and laws but does not contain full financial statements or detailed financial results. The document length is 2915 characters, which is relatively short and appears to be a formal opinion or statement rather than a full report. It is not an announcement of a report publication but a standalone opinion document. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related disclosure and independent directors' opinions rather than a full annual report, audit report, or other specific report types.
2016-03-29 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding the use of funds by controlling shareholders and related parties, specifically for the year ending December 31, 2015. It references an audit report issued by Da Hua Certified Public Accountants with an unqualified opinion on the 2015 financial statements. The document includes detailed tables summarizing non-operating fund occupation and related party transactions. It cites regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding disclosure of related party transactions and fund occupation. The document is a standalone special explanation report related to audit findings on related party fund usage, not a full annual report or interim report. It is not a general audit report on financial statements but a specific audit-related disclosure on related party fund occupation. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report focusing on a specific issue (related party fund occupation) and includes audit procedures and findings. The document length (9862 characters) is sufficient to be a full report, not just an announcement. Therefore, the classification is AR with high confidence. FY 2015
2016-03-29 Chinese
关于为参股公司提供担保的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding providing a guarantee for a loan to an affiliated company. It includes details about the guarantee, the affiliated company, board opinions, and independent directors' opinions. The document is relatively short (1403 characters) and does not contain financial statements or detailed financial performance data. It is an announcement about a corporate action (providing a guarantee) rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or officer attestation. The content aligns best with a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2016-03-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.